Indication

Treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments.

Medicine details

Medicine name:
fostamatinib (Tavlesse)
SMC ID:
SMC2300
Pharmaceutical company
Grifols UK Ltd
BNF chapter
Nutrition and blood
Submission type
Full
Publication due date:
11 January 2021
SMC meeting date:
01 December 2020
Patient group submission deadline:
05 October 2020